IGF1 and acromegaly: While our patient's acromegaly improved significantly with decline in GH and IGF1 levels when octreotide was switched to pasireotide, he continued to have intermittent hypercortisolaemia and his glycaemic control deteriorated significantly requiring a new anti-diabetic medication.